Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1 A*02:01 TCR-T
- Development stage
- Unknown
- Lead developer
- Anocca
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anocca's lead program is an autologous T-cell receptor (TCR) engineered T-cell therapy designed to target the NY-ESO-1 (New York esophageal squamous cell carcinoma 1) antigen. The therapy specifically recognizes the NY-ESO-1 peptide when presented by the HLA-A*02:01 major histocompatibility complex (MHC) class I molecule. NY-ESO-1 is a cancer-testis antigen that is highly expressed in several solid tumors—including melanoma, synovial sarcoma, bladder cancer, and esophageal cancer—while remaining largely absent from healthy adult tissues, making it an ideal target for immunotherapy. By engineering a patient's own T cells with high-affinity TCRs identified through Anocca's proprietary platform, the therapy aims to induce potent, antigen-specific destruction of tumor cells. It is currently in Phase 1 clinical development.
- Other names
- Anocca NY-ESO-1 TCR-TNY-ESO-1 HLA-A*02:01 TCR-T cell therapy
02
Targets
NY-ESO-1 (New york esophageal squamous cell carcinoma 1)pMHC-I (Peptide–MHC class I complex)
Beyond the preview
Go deeper on NY-ESO-1 A*02:01 TCR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1 A*02:01 TCR-T.